“attempt to convince posters that Not Reimbursed means Reimbursed and Nonproprietary means proprietary is telling”
I “attempted” no such thing .. calm down 🤣
The recent update to the NHS HCD list simply indicates that NHS can pay for murcidencel if IFR is approved—that’s the current plain meaning of the entry. Fact ✅
In other words, now a doctor may submit an IFR for DCVax-L (the brand name or generic name) and NHS can approve the request or not.
Murcidencel (also known as DCVax-L) is not routinely commissioned by NHS England. However, it has been added to the NHS High Cost Drugs (HCD) list, making it accessible through the Individual Funding Request (IFR) process for patients with exceptional clinical circumstances.
What This Means for Patients
The inclusion of murcidencel on the HCD list indicates that while it is not broadly available, clinicians can request its funding on a case-by-case basis via an IFR. This process is applicable when a clinician believes that a patient’s clinical situation is significantly different from others with the same condition and that the patient is likely to benefit more from the treatment than typical patients.
Key Points:
• Not Routinely Commissioned: Murcidencel is not part of the standard NHS treatment offerings. • Available via IFR: Clinicians can apply for its use through the IFR process for patients with exceptional clinical circumstances. • Case-by-Case Basis: Each application is individually assessed, and approval is not guaranteed.
In summary, murcidencel is not routinely funded by the NHS but can be accessed through an Individual Funding Request if a clinician deems it appropriate for a patient with exceptional clinical needs.[/color]
Market Data 
Markets 
